SALIX PHARMACEUTICALS LTD
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | $403.0M | $202.6M | $735.4M | $540.5M | $337.0M | $232.9M |
| Operating income | −$490.1M | $252.3M | $172.1M | $115.9M | −$6.2M | −$40.1M |
| Net income | −$34.6M | $22.4M | $64.2M | $87.4M | −$27.1M | −$43.6M |
| Total assets | $4.12B | $2.93B | $1.87B | $1.30B | $851.5M | — |
| Total liabilities | — | — | — | — | — | — |
| Equity | $238.2M | $728.6M | $560.5M | $549.6M | $401.9M | $370.0M |
| EPS (diluted) | $-0.55 | $0.35 | $1.01 | $1.44 | $-0.47 | $-0.88 |
| Shares out. | 63.3M | 61.1M | 59.4M | 59.2M | 58.1M | 49.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- −121.6%
- Net margin
- −8.6%
- Return on equity
- −14.5%
- Return on assets
- −0.8%
- Return on capital (ROCE)
- −18.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $3.76
- Revenue growth (YoY)
- 98.9%
- Net income growth (YoY)
- −254.1%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Accruals / assets
- −0.9%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- PLENVUMay 4, 2018
- TRULANCEJan 19, 2017
- RELISTORJul 19, 2016
- UCERISJan 14, 2013
- APRISOOct 31, 2008
- FENOGLIDEAug 10, 2007
- ZEGERIDFeb 27, 2006
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Scruggs Rick DOfficer — Executive Vice President | Apr 1, 2015 | U | 26,956 | $173.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 1, 2015
- Entered a material agreement · Other material eventMar 16, 2015
- Results of operationsMar 2, 2015
- Other material eventFeb 27, 2015
- Other material eventFeb 23, 2015
- Entered a material agreement · Other material eventFeb 23, 2015
- Other material eventFeb 17, 2015
- Other material eventFeb 13, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.